TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multi-center, Double-blind, Placebo-controlled, Cross-over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
Brief Summary: This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory classroom setting.


Options:
A: Arm Label: Placebo First, then ORADUR®; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo First, then ORADUR® | Arm Label: ORADUR® First, then Placebo; Type: EXPERIMENTAL; Interventions: Drug: ORADUR® First, then Placebo | Intervention Type: DRUG; Name: Placebo First, then ORADUR®; Assigned to Arm(s): Placebo First, then ORADUR® | Intervention Type: DRUG; Name: ORADUR® First, then Placebo; Assigned to Arm(s): ORADUR® First, then Placebo
B: Arm Label: Focalin XR then Adderall XR; Type: EXPERIMENTAL; Interventions: Drug: Dexmethylphenidate, Drug: Mixed Amphetamine Salts, ER, Drug: placebo | Arm Label: Adderall XR then Focalin XR; Type: EXPERIMENTAL; Interventions: Drug: Dexmethylphenidate, Drug: Mixed Amphetamine Salts, ER, Drug: placebo | Intervention Type: DRUG; Name: Dexmethylphenidate; Assigned to Arm(s): Adderall XR then Focalin XR, Focalin XR then Adderall XR | Intervention Type: DRUG; Name: Mixed Amphetamine Salts, ER; Assigned to Arm(s): Adderall XR then Focalin XR, Focalin XR then Adderall XR | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Adderall XR then Focalin XR, Focalin XR then Adderall XR
C: Arm Label: Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) | Arm Label: Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR); Assigned to Arm(s): Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg, Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Clopidogrel is a antiplatelet agent and is effective at reducing intimal hyperplasia in animal models of thrombosis.Several large clinical trials have demonstrated that clopidogrel with aspirin can reduce ischemic events and mortality in patients with atherosclerotic disease,therefore the combination of two antiplatelets might be useful to prevent patients received coronary artery bypass graft surgery from Saphenous vein graft disease. the aim of this study is to estimate the safety and efficacy of clopidogrel and aspirin therapy versus aspirin alone in patients after CABG.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: clopidogrel and aspirin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin | Intervention Type: DRUG; Name: clopidogrel and aspirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): 2
B: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin monotherapy | Arm Label: Aspirin,Clopidogrel; Type: EXPERIMENTAL; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin monotherapy; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel
C: Arm Label: aspirin low responders monotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: aspirin low responders dual antiplatelet therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): aspirin low responders dual antiplatelet therapy
D: Arm Label: ASS + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: clopidogrel | Arm Label: ASS + Plavix; Type: ACTIVE_COMPARATOR; Interventions: Drug: clopidogrel | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): ASS + Placebo, ASS + Plavix

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Early Skin to Skin Contact on Breast Feeding Behaviour in Term Newborns: A Randomized Controlled Trial
Brief Summary: Aims and Objectives

Aim

To determine the effect of delivery room Skin To Skin contact on breast feeding behavior of term neonates born by normal vaginal delivery at 36-48 hours.

Objectives Primary objective To determine the effect of delivery room Skin To Skin contact on breast feeding behaviour of term neonates born by normal vaginal delivery, between 36-48 hours (as measured by Infant Breast Feeding Score) by video recording using a randomized controlled design.

Secondary objectives To determine the effect of delivery room Skin to Skin contact on

1. Salivary cortisol at 6 hours as measured by electrochemiluminescence immunoassay (ECLIA)
2. Weight at 48 hours as measured by digital infant weighing scale.
3. Maternal perception of breast milk output, breast consistency, infant's feeding and activity at 36-48 hours as measured by a score graded as very satisfied, satisfied, acceptable and not satisfied.
4. Number and duration of feeding sessions till 48 hrs according to the mother as assessed at 48 hours
5. Breast feeding rates at 6 weeks measured at the time of vaccination at the time of visit to the hospital for the same or as asked by telephonic conversation.

Hypothesis

Infants receiving skin to skin contact when compared with neonates not receiving it, demonstrate better breast feeding behaviour.


Options:
A: Arm Label: Patterned Experience Group; Type: EXPERIMENTAL; Interventions: Behavioral: Patterned Experience | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patterned Experience; Assigned to Arm(s): Patterned Experience Group
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Intervention group | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
C: Arm Label: skin to skin contact; Type: EXPERIMENTAL; Interventions: Other: skin to skin contact | Arm Label: Control group; Type: EXPERIMENTAL; Interventions: Other: Control group | Intervention Type: OTHER; Name: skin to skin contact; Assigned to Arm(s): skin to skin contact | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
D: Intervention Type: DEVICE; Name: partial-vacuum milk bottle; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: anti-vacuum milk bottle; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carbonated Soft Drinks May Alter Appetite Sensation and Appetite-Regulating Hormone Level and Lead to Increased Energy Intake.
Brief Summary: Compared to solid foods, the nutritional energy of drinks may bypass the appetite regulation leading to obesity development. Although drinks sweetened with aspartame are available the anticipated positive effect of these drinks on obesity development has not been convincing. However, the mechanisms linking drinks intake to obesity are yet to be clarified.

The investigators aim is to investigate the short-term effects of soft drinks (sugar-sweetened and artificially sweetened (aspartame)), milk and water on the concentration of circulating appetite-regulating hormones, the subjective sensations of hunger and satiety (measured by visual analogue scales) and energy intake. The study is a crossover, intervention trial with 24 overweight, healthy volunteers. The subjects will be tested on four separate days for four hours. Each test day a preload drink (sugar-sweetened soft drink, aspartame-sweetened soft drink, semi-skimmed milk or water) is served.

The investigators expect to clarify the mechanisms linking drinking habits to obesity development and provide scientifically based nutritional guidelines.


Options:
A: Arm Label: Sugar-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Sugar-sweetened soft drink | Arm Label: Aspartame-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Aspartame-sweetened soft drink | Arm Label: Semi-skimmed milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Semi-skimmed milk | Arm Label: Water; Type: PLACEBO_COMPARATOR; Interventions: Other: Water | Intervention Type: OTHER; Name: Sugar-sweetened soft drink; Assigned to Arm(s): Sugar-sweetened soft drink | Intervention Type: OTHER; Name: Aspartame-sweetened soft drink; Assigned to Arm(s): Aspartame-sweetened soft drink | Intervention Type: OTHER; Name: Semi-skimmed milk; Assigned to Arm(s): Semi-skimmed milk | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Water
B: Arm Label: Supplementary water; Type: EXPERIMENTAL; Interventions: Other: Water | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Supplementary water
C: Arm Label: Menu Only intervention; Type: EXPERIMENTAL; Interventions: Other: Menu Only | Arm Label: Menu Plus Intervention; Type: EXPERIMENTAL; Interventions: Other: Menu Plus intervention | Intervention Type: OTHER; Name: Menu Only; Assigned to Arm(s): Menu Only intervention | Intervention Type: OTHER; Name: Menu Plus intervention; Assigned to Arm(s): Menu Plus Intervention
D: Arm Label: Low intensity arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary, physical activity and sleeping | Arm Label: High intensity arm; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary, physical activity and sleeping | Intervention Type: BEHAVIORAL; Name: Dietary, physical activity and sleeping; Assigned to Arm(s): High intensity arm, Low intensity arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma
Brief Summary: The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo. Tiotropium inhalation solution delivered by the Respimat® inhaler will be examined as add-on controller therapy on top of usual care in patients with severe persistent asthma. The primary objective of each trial is to evaluate the long term efficacy of tiotropium over placebo on top of usual care in patients with severe persistent asthma as determined by pulmonary function testing, effects on asthma exacerbations, effects on quality of life, on asthma control and health care resource utilisation. The secondary objective of each trial is to compare the long term safety of tiotropium with placebo in this patient population.


Options:
A: Arm Label: tiotropium 5mcg/day; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5mcg/day | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium 5mcg/day; Assigned to Arm(s): tiotropium 5mcg/day | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: tiotropium 2.5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 1.25 mcg (2 actuations/day) | Arm Label: tiotropium 18 mcg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium 18 mcg | Arm Label: tiotropium 5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 2.5 mcg (2 actuations/day) | Intervention Type: DRUG; Name: tiotropium 18 mcg; Assigned to Arm(s): tiotropium 18 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 1.25 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 2.5 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 2.5 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 5 mcg and placebo
C: Arm Label: tiotropium 5mcg/day; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5mcg/day | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium 5mcg/day; Assigned to Arm(s): tiotropium 5mcg/day | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol xinafoate; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone
Brief Summary: The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study. Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents. Cediranib is a new drug that has not yet been approved for this disease. This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo ("inactive substance") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.


Options:
A: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Rindopepimut/GM-CSF plus Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF, Drug: Temozolomide | Arm Label: KLH plus Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Drug: KLH | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): KLH plus Temozolomide, Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): KLH plus Temozolomide
C: Arm Label: Arm 1 - Short Course Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy | Arm Label: Arm 2 - Standard Course Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 1 - Short Course Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 2 - Standard Course Radiotherapy
D: Arm Label: Cediranib 30mg; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Arm Label: Cediranib 20mg + lomustine; Type: OTHER; Interventions: Drug: Cediranib, Drug: Lomustine Chemotherapy | Arm Label: Lomustine and Placebo Cediranib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine Chemotherapy, Drug: Placebo Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 30mg | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 20mg + lomustine | Intervention Type: DRUG; Name: Lomustine Chemotherapy; Assigned to Arm(s): Cediranib 20mg + lomustine, Lomustine and Placebo Cediranib | Intervention Type: DRUG; Name: Placebo Cediranib; Assigned to Arm(s): Lomustine and Placebo Cediranib

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2a Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) In Cystic Fibrosis Patients With Chronic Infections Due To Pseudomonas Aeruginosa.
Brief Summary: A major factor in the respiratory health of cystic fibrosis (CF) subjects is acquisition of chronic Pseudomonas aeruginosa infections. The infection rate with P. aeruginosa increases with age and by age 18 years, 80% of CF subjects in the U.S. are infected. Liposomal Amikacin for Inhalation (Arikace™) is a sterile aqueous liposomal suspension consisting of amikacin sulfate encapsulated in liposomes. This formulation of amikacin maximizes the achievable dose and delivery to the lungs of subjects infected via a nebulizer. Because liposome particles are small enough to penetrate and diffuse through sputum into the bacterial biofilm, they deposit drug in close proximity to the bacterial colonies, thus improving the bioavailability of amikacin at the infection site. The clinically achievable doses of amikacin in the LAI formulation can effectively increase the half-life of the drug in the lungs, and decrease the potential for systemic toxicity. LAI offers several advantages over current therapies in treating CF subjects with chronic infection caused by P. aeruginosa.


Options:
A: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A
B: Arm Label: AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZLI, Drug: Tobramycin inhalation solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match AZLI, Drug: Tobramycin inhalation solution | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI | Intervention Type: DRUG; Name: Placebo to match AZLI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tobramycin inhalation solution; Assigned to Arm(s): AZLI, Placebo
C: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days
D: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Randomised, 2 Period Cross Over Study to Determine the Comparative Bioavailability of Two Different Oral Formulations of AZD2281 in Cancer Patients With Advanced Solid Tumours
Brief Summary: The purpose of this phase I randomised cross over study is to determine and compare the bioavailability of two different oral formulations of AZD2281 in advanced solid tumour cancer patients


Options:
A: Arm Label: Treatment A; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: Treatment B; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: Treatment C; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): Treatment A, Treatment B, Treatment C
B: Arm Label: KU-0059436; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436
C: Arm Label: Arm 1 (ceralasertib+olaparib); Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Ceralasertib | Arm Label: Arm 2 (olaparib monotherapy); Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Arm 3 (placebo); Type: EXPERIMENTAL; Interventions: Drug: Placebo to match olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm 1 (ceralasertib+olaparib), Arm 2 (olaparib monotherapy) | Intervention Type: DRUG; Name: Ceralasertib; Assigned to Arm(s): Arm 1 (ceralasertib+olaparib) | Intervention Type: DRUG; Name: Placebo to match olaparib; Assigned to Arm(s): Arm 3 (placebo)
D: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Caloric Restriction, Exercise, and Glucoregulation in Humans
Brief Summary: Weight loss induced by caloric restriction alone (CR) and by exercise alone (EX) result in similar effects on blood glucose and insulin. The purpose of this study is to assess the hypothesis that weight loss through caloric restriction plus exercise will result in greater improvements on glucose tolerance and insulin action than similar weight losses through CR or EX alone.


Options:
A: Arm Label: Calorie restriction; Type: ACTIVE_COMPARATOR; Interventions: Other: Calorie Restriction | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: Calorie restriction and exercise; Type: EXPERIMENTAL; Interventions: Other: Calorie Restriction and Exercise | Intervention Type: OTHER; Name: Calorie Restriction; Assigned to Arm(s): Calorie restriction | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: OTHER; Name: Calorie Restriction and Exercise; Assigned to Arm(s): Calorie restriction and exercise
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Arm Label: Control Group (delayed intervention); Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Intervention Type: OTHER; Name: Weight loss intervention; Assigned to Arm(s): Control Group (delayed intervention), Intervention Group
C: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A

Answer: A